Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NLG802 |
Synonyms | |
Therapy Description |
NLG802 is a prodrug of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor indoxomid, which reduces production of kynurenine from tryptophan and potentially increases anti-tumor immune response (PMID: 32422549). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NLG802 | NLG-802|NLG 802 | IDO1 Inhibitor 12 | NLG802 is a prodrug of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor indoxomid, which reduces production of kynurenine from tryptophan and potentially increases anti-tumor immune response (PMID: 32422549). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03164603 | Phase I | NLG802 | NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors | Completed | USA | 0 |